首页> 美国卫生研究院文献>AIDS Research and Human Retroviruses >Expression of Interleukin-15 and Interleukin-15Rα in Monocytes of HIV Type 1-Infected Patients with Different Courses of Disease Progression
【2h】

Expression of Interleukin-15 and Interleukin-15Rα in Monocytes of HIV Type 1-Infected Patients with Different Courses of Disease Progression

机译:不同病程的HIV-1感染者单核细胞中白细胞介素15和白细胞介素15Rα的表达

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Interleukin-15 (IL-15) enhances the effector mechanisms of anti-HIV immune responses and thus is considered a potential adjuvant of HIV-1 vaccine. However, there are a lack of data concerning the relationships between IL-15 expression and regulation in HIV-1-infected patients and the course of disease progression. We found that IL-15, but not IL-15Rα, is expressed at significantly higher levels in the CD14+ monocytes [stimulated or not with interferon (IFN)-γ] of long-term nonprogressors (LTNP) than in those of HIV-1 progressors or healthy controls. There was no between-group difference in the amounts of soluble IL-15 released from the cells. We also found that like the healthy controls, the LTNP expressed the IL-15 and IL-15Rα genes in a more coordinated manner than the progressors. Our findings show that there are significant differences in IL-15 expression between patients with different courses of HIV infection, and that the coordinated expression of the IL-15 and IL-15Rα genes is dysregulated in patients with progressive disease. They also provide important information concerning the mechanisms of infection and the potential use of IL-15 as a therapeutic agent.
机译:白介素15(IL-15)增强了抗HIV免疫应答的效应器机制,因此被认为是HIV-1疫苗的潜在佐剂。但是,缺乏有关感染HIV-1的患者中IL-15表达与调节之间的关系以及疾病进展过程的数据。我们发现IL-15,而不是IL-15Rα,在长期非进展性(LTNP)CD14 + 单核细胞[受干扰素(IFN)-γ刺激或未受干扰)中以更高的水平表达。 ),而不是HIV-1进展者或健康对照者。从细胞释放的可溶性IL-15的量之间没有组间差异。我们还发现,与健康对照组一样,LTNP以比进展者更协调的方式表达IL-15和IL-15Rα基因。我们的发现表明,在不同HIV感染病程的患者之间,IL-15表达存在显着差异,并且在进行性疾病患者中,IL-15和IL-15Rα基因的协同表达失调。他们还提供了有关感染机制以及IL-15作为治疗剂的潜在用途的重要信息。

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号